Scholarlink

<p>Post-COVID-19 condition (PCC) develops after the acute phase of the SARS-CoV-2 infection with cognitive symptoms in 7.2-59.2% of cases, affecting primarily executive function, memory and attention-processing speed. MicroRNAs (miRNAs) are vital neurophysiological regulators and potential non-invasive biomarkers. This study analyzes a complete neuropsychological battery in 48 PCC patients, grouped into cognitively impaired (PCC-CI) and cognitively healthy (PCC-CH), and 16 controls; and quantifies plasma miRNAs using a TaqMan OpenArray or qRT-PCR. Results showed 13 miRNAs differentially expressed in PCC-CI as compared to PCC-CH patients. Functional analysis using predictive tools revealed associations with the Forkhead box O (FoxO) signaling pathway, Hippo signaling pathway or neurotrophin signaling pathway, among others, all involved in cognitive decline over time. Moreover, miR-369-3p, miR-448, miR-450a-5p and miR-483-3p were validated to be differentially expressed in additional samples of PCC and shown direct correlations with cognitive variables related to memory, processing speed and executive functions. Finally, a miR-448 and miR-450a signature showed good predictive values as biomarkers of cognitive impairment in PCC patients. In conclusion, a miR-448 and miR-450a signature showed potential as biomarkers to distinguish cognitively impaired patients in the post-COVID condition, indicating their potential to be applied in medical practice in the future.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

CircuLating micrornas in post-COVID-19 patients and its association with cognitive impairment

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月24日

查看全文
  • Gemma Carreras-Badosa,
  • Mar Ariza,
  • Andrea Riberas-Sánchez,
  • Neus Cano,
  • Olga Gelonch,
  • Yemila Plana,
  • Paloma Salas,
  • Maite Garolera,
  • Gemma Huguet,
  • Elisabet Kádár,
  • Meritxell Vilaseca,
  • Mikel Aldaba,
  • Barbara Segura,
  • Javier Béjar,
  • Antonio Arévalo,
  • Jose Antonio Bernia,
  • Silvia Moron

摘要

Post-COVID-19 condition (PCC) develops after the acute phase of the SARS-CoV-2 infection with cognitive symptoms in 7.2-59.2% of cases, affecting primarily executive function, memory and attention-processing speed. MicroRNAs (miRNAs) are vital neurophysiological regulators and potential non-invasive biomarkers. This study analyzes a complete neuropsychological battery in 48 PCC patients, grouped into cognitively impaired (PCC-CI) and cognitively healthy (PCC-CH), and 16 controls; and quantifies plasma miRNAs using a TaqMan OpenArray or qRT-PCR. Results showed 13 miRNAs differentially expressed in PCC-CI as compared to PCC-CH patients. Functional analysis using predictive tools revealed associations with the Forkhead box O (FoxO) signaling pathway, Hippo signaling pathway or neurotrophin signaling pathway, among others, all involved in cognitive decline over time. Moreover, miR-369-3p, miR-448, miR-450a-5p and miR-483-3p were validated to be differentially expressed in additional samples of PCC and shown direct correlations with cognitive variables related to memory, processing speed and executive functions. Finally, a miR-448 and miR-450a signature showed good predictive values as biomarkers of cognitive impairment in PCC patients. In conclusion, a miR-448 and miR-450a signature showed potential as biomarkers to distinguish cognitively impaired patients in the post-COVID condition, indicating their potential to be applied in medical practice in the future.